Core Viewpoint - The company, Blue Horizon Biological, announced the approval of its subsidiary Qingdao Kangdian Animal Pharmaceutical Co., Ltd. for two new veterinary drugs, "Fluralaner Drops (for dogs)" and "Fluralaner Drops (for cats)", classified as Class II new veterinary drugs by the Ministry of Agriculture and Rural Affairs [2]. Summary by Categories - **Company Announcement** - Blue Horizon Biological has received approval for its subsidiary's new veterinary drugs [2]. - The Ministry of Agriculture and Rural Affairs issued the New Veterinary Drug Registration Certificate (Announcement No. 949) for these products [2]. - **Product Details** - The approved products include "Fluralaner Drops (for dogs)" and "Fluralaner Drops (for cats)" [2].

Core Viewpoint - The company, Reap Bio (300119), announced its share repurchase and dividend distribution plans, highlighting its commitment to returning value to shareholders through significant cash dividends and stock repurchases [1] Group 1: Share Repurchase - In 2023 and 2024, the company plans to repurchase a total of 10.68 million shares [1] - The total amount allocated for the share repurchase is 190 million RMB [1] Group 2: Dividend Distribution - Since its listing, the company has distributed a total of 1.371 billion RMB in cash dividends [1] - The average dividend payout ratio stands at 44.32% [1] - The company has executed four stock splits, resulting in a 5.27 times expansion of its share capital compared to before its initial public offering [1]

Group 1 - The company views the pet pharmaceutical sector as one of its key development directions and is optimistic about its future prospects [2] - The company has adjusted resource allocation to increase investment in pet pharmaceutical research and market channel development [2] - The company has established an independent and specialized research team for pet pharmaceuticals and has obtained seven product approvals in the first half of the year, significantly expanding its product line [2] Group 2 - The company's pet pharmaceutical products mainly cover various subfields, including antiparasitics, analgesics, dermatological medications, internal medicine, and functional health products [2]

Core Viewpoint - The company reported significant growth in both revenue and net profit for the first half of the year, indicating strong operational performance and market demand [1] Financial Performance - The company achieved operating revenue of 822.20 million yuan, an increase of 88.45% compared to the same period last year [1] - The net profit attributable to shareholders reached 117.18 million yuan, reflecting a substantial growth of 325.88% year-on-year [1] Segment Performance - Sales revenue from chemical drug formulations increased by 54.23% year-on-year, although the gross margin decreased by 0.36% [1] - Sales revenue from veterinary raw materials surged by 199.01% compared to the previous year, with a gross margin improvement of 27.14% [1] Financial Impact - The redemption of convertible bonds led to a reduction in interest expenses by 11.31 million yuan, which had a certain impact on net profit [1] - The company declared a cash dividend of 1.00 yuan per 10 shares to all shareholders [1]